Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active crohns disease

PharmacoEconomics

Volumn 27, Issue 7, 2009, Pages 609-621

  Yu, Andrew P ^a   Johnson, Scott ^a   Wang, Si Tien ^a   Atanasov, Pavel ^a   Tang, Jackson ^a   Wu, Eric ^a   Chao, Jingdong ^b   Mulani, Parvez M ^b  

^a ANALYSIS GROUP   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ARTICLE; COST OF ILLNESS; COST UTILITY ANALYSIS; CROHN DISEASE; DRUG COST; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 68949098309     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11312710-000000000-00000     Document Type: Article

References (31)

1. Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16 (1): 51-60
2. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastro-enterology 1999; 117 (1): 49-57
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369 (9573): 1641-1657
4. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30 (7): 699-706
5. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 24 (2): 319-328
6. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospi-talizations and surgeries. Am J Gastroenterol 2004; 99 (1): 91-96
7. Ghosh S. Anti-TNF therapy in Crohn's disease. Novartis Found Symp 2004; 263: 193-205; discussion 205-218
8. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117 (4): 761-769
9. Koelewijn C, Schrijvers A, Oldenburg B. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use. Neth J Med 2006; 64 (7): 212-218
10. Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. Biodrugs 2007; 21 (2): 125-32; discussion 133-134
11. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109 (1): 129-135
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541-1549
13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126 (2): 402-413 (Pubitemid 38182297)
14. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9): 876-885
15. Sandborn WJ, Hanauer S, Loftus Jr EV, et al. An open-label study of the human TNF antagonist monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99 (10): 1984-1989
16. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease: safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25 (7): 787-796
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52-65
18. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232-1239 (Pubitemid 47300424)
19. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323-33; quiz 591
20. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate to severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009; 104: 1170-1179
21. WAC 2007 adalimumab cost. AnalySource® Online [online]. Available from URL: http://www.analysource.com [Accessed 2007 Nov 30]
22. Centers for Medicare and Medicaid Services. 2007 Medicare physician fee schedule [online]. Available from URL http:// www.cms.hhs.gov/physicianfeesched/ pfsfrn/ItemDetail.asp? ItemID = CMS1 188377 [Accessed 2009 Jul 23]
23. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135 (5): 1493-1499
24. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000; 95 (2): 524-530
25. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn disease: a payor perspective. Am J Gastroenterol 2000; 95 (8): 1955-1960
26. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14 (4): 318-327
27. Gregor J, McDonald J, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997; 3 (4): 265-276
28. Humira [package insert]. Abbott Park (IL); Abbott Laboratories, Inc., 2008 [online]. Available from URL: http://www.rxabbott.com/pdf/humira.pdf [Accessed 2008 Dec 8]
29. Remicade [package insert]. Malvern (PA): Centocor, Inc., 2007 [online]. Available from URL: http://www. remicade.com/remicade/assets/HCP-PPI.pdf [Accessed 2008 Dec 8]
30. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
31. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006; 13 (6): 502-506